Investigating how certain immune cells interact with prostate cancer in the bone.
Official title: Understanding the influence of bone-metastatic prostate cancer and mesenchymal stromal cells on γδ T cells, in the bone microenvironment.
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-10798138 · Data updated 2026-11-12
This study is looking at how special immune cells can be changed to better fight prostate cancer that has spread to the bones, and it’s testing a drug to help make these immune cells even more effective, all with the goal of finding better treatments for patients with advanced prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | March 9, 2020 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $413,715 |
| NIH project number | 5R01CA241169-05 |
| Project ID | NIH-10798138 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with castrate-resistant prostate cancer that has metastasized to the bone.
✕Less likely to help
Patients with early-stage prostate cancer or those whose cancer has not spread to the bone may not benefit from this research.
What this research studies
This research focuses on understanding how a specific type of immune cell, called γδ T cells, interacts with bone-metastatic prostate cancer and mesenchymal stromal cells in the bone environment. The approach involves modifying these T cells to better target cancer cells and using a drug called zoledronate to enhance their effectiveness. By studying these interactions, the research aims to develop new immunotherapy strategies that could improve treatment outcomes for patients with advanced prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with castrate-resistant prostate cancer that has spread to the bone.
How similar studies have gone: Other research has shown promise in using modified T cells for cancer treatment, suggesting that this approach could be effective, although the specific combination being tested here is novel.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Abate-Daga, Daniel — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Abate-Daga, Daniel
Related research
Other NIH-funded projects on the same topics.
-
Combination immunotherapy with radioligand therapy for metastatic prostate cancer
A study aims to help men with advanced prostate cancer by combining immune therapy with targeted radiation to boost the body’s own defense against cancer.
-
Understanding what drives lethal metastatic prostate cancer in men
This grant looks at why some prostate cancers become deadly and spread, using patient-derived cells and mouse models.
-
Off-the-shelf tumor cell vaccine tailored to your tumor’s HLA type for advanced prostate cancer
A new vaccine approach uses donor cancer cells matched to a patient’s immune system to help fight advanced prostate cancer.
-
ASH1L’s role in metastatic prostate cancer and its immune environment
Aims to understand how the ASH1L gene helps prostate cancer spread and how it shapes the immune environment in bone metastases so future therapies can target this process.
-
Molecular drivers of lineage changes and new therapies for metastatic prostate cancer
A multi-year study at a major university will explore how metastatic prostate cancer changes its cell type and how to target those changes to help patients.
-
How gut bacteria may affect prostate cancer therapy and resistance
A new study looks at how gut bacteria make compounds that influence prostate cancer treatments and may drive resistance to therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.